Autopsy report · NCT03984019

Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung Metastasis

“Slow accrual due to COVID-19 and lower accrual than expected.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 8 months before it started.
• Ran for about 2 years 3 months before it stopped.
• 10 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

The Netherlands Cancer Institute

Sponsor type

University, hospital or other

Conditions

Lung Cancer Stage I; Lung Cancer Stage II; Lung Metastases

Interventions

Cardiac condition measurements

Participants

10

Sites

3

Countries

Netherlands

Trials that died the same way

• Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
  “Low accrual due to COVID-19 pandemic.” (84% match in meaning)
• The Use of a Point-of-care Thoracic Ultrasound Protocol for Hospital Medical Emergency Teams
  “Slow inclusion rate (partly due to Covid-19)” (71% match in meaning)
• Optimal Endoscopic Suturing Pattern for Esophageal Stent Fixation
  “Accrual difficulties: This trial was initiated prior to COVID-19 and interrupted by the pandemic for a significant length of time.” (68% match in meaning)
• Long Term Minor Sibling Donor Well-Being
  “Slow accrual.” (66% match in meaning)
• Prevalence and Impact on QoL From Ototoxicity in Cancer Survivors
  “due to COVID-19” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.